Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review

Pediatr Blood Cancer. 2021 Jul;68(7):e29044. doi: 10.1002/pbc.29044. Epub 2021 Apr 12.

Authors

Federica Sora^{1

2}, Mario Annunziata³, Luca Laurenti^{1

2}, Sabrina Giammarco¹, Patrizia Chiusolo^{1

2}, Idanna Innocenti², Francesco Autore², Elisabetta Metafuni², Eugenio Galli², Andrea Bacigalupo^{1

2}, Felicetto Ferrara³, Simona Sica^{1

2}

Affiliations

¹ Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
³ Division of Hematology, Ospedale Cardarelli, Naples.

PMID: 33844429
DOI: 10.1002/pbc.29044

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Antibodies, Bispecific / therapeutic use*
Antineoplastic Agents / therapeutic use
Down Syndrome* / complications
Down Syndrome* / drug therapy
Humans
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / complications
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Antibodies, Bispecific
Antineoplastic Agents
blinatumomab

Associated data

ClinicalTrials.gov/NCT03914625